contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


balance-sheet-shows-that-the-equity-in-lidds-ab-is-less-than-half-of-the-registered-share-capital-and-the-board-will-therefore-convene-a-first-control-meeting

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patented and clinically tested drug delivery technology. The properties of the products form the basis of the LIDDS technology platform for the development of injectable pharmaceutical products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System, and the company is headquartered in Uppsala.

LIDDS

GOTHENBURG, SWEDEN - As announced in a press release on 22 April 2025, the Board of Directors of LIDDS AB (publ) ("Lidds" or the "Company") found reason to believe that the equity was less than...

<div class="mfn-preamble"><p><strong>GOTHENBURG, SWEDEN - As announced in a press release on 22 April 2025, the Board of Directors of LIDDS AB (publ) ("Lidds" or the "Company") found reason to believe that the equity was less than half of the registered share capital and therefore decided to prepare a balance sheet for liquidation purposes. The Board of Directors of Lidds has prepared the balance sheet for liquidation purposes, and it has been reviewed by the Company's auditor. The balance sheet for liquidation purposes shows that the Company's equity is less than half of the registered share capital of SEK 7,232,556.</strong></p></div><div class="mfn-body"><p>Lidds and the Board of Directors have worked intensively during the spring to try to generate equity for the Company but have not yet found a solution for its strained financial situation in the short and medium term.<br>The Board of Directors will therefore convene a general meeting (the so-called first control meeting according to the Swedish Companies Act). The notice of the Annual General Meeting, which will also serve as the First Control Meeting, will be published through a separate press release shortly.</p></div><div class="mfn-footer mfn-contacts mfn-cb73eb895ad4"><p><strong class="mfn-heading-1">For additional information, please contact</strong></p><hr><p>Mats Wiking, CEO and CFO<br>Phone: +46 (0)70 620 04 00<br>E-mail: mats.wiking<a rel="noopener" href="mailto:jenni.bjornulfson@liddspharma.com">@liddspharma.com</a></p><p>LIDDS’ Certified Adviser is Redeye AB</p></div><div class="mfn-footer mfn-about mfn-dcb9e4cb41ff"><p><strong class="mfn-heading-1">LIDDS in brief:</strong></p><hr><p>LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-24 22:45 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/b1c904ee-f555-451e-9fc3-92eb11a95950/balance-sheet-shows-that-the-equity-in-lidds-ab-is-less-than-half-of-the-registered-share-capital-and-the-board-will-therefore-convene-a-first-control-meeting.pdf" class="mfn-generated mfn-primary">Balance Sheet shows that the Equity in LIDDS AB is Less than Half of the Registered Share Capital and the Board will therefore convene a First Control Meeting</a></p></div>

Balance Sheet shows that the Equity in LIDDS AB is Less than Half of the Registered Share Capital and the Board will therefore convene a First Control Meeting

Talouden myyttejä murtamassa: Saksan teollisuus on menneen talven lumia

Federal Reserven korkopäätös: Riidankylväjät vauhdissa

On pakko painaa pitkää päivää? Ekonomisti fundeeraa

Nousuviikko takana, USA:n työllisyystaantuma ei edelleenkään luvuissa

Taloustieteen myyttejä murtamassa: Datakeskusinvestoinnit johtavat aina vain parempaan tekoälyyn